Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD

0.1851  -0.03 (-12.85%)

After market: 0.185 0 (-0.05%)

Fundamental Rating

2

Overall CDIO gets a fundamental rating of 2 out of 10. We evaluated CDIO against 563 industry peers in the Biotechnology industry. The financial health of CDIO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CDIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CDIO had negative earnings in the past year.
CDIO had a negative operating cash flow in the past year.
In the past 5 years CDIO always reported negative net income.
CDIO had negative operating cash flow in 4 of the past 5 years.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

CDIO's Return On Assets of -78.98% is on the low side compared to the rest of the industry. CDIO is outperformed by 68.92% of its industry peers.
CDIO has a Return On Equity (-87.71%) which is in line with its industry peers.
Industry RankSector Rank
ROA -78.98%
ROE -87.71%
ROIC N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDIO has more shares outstanding than it did 1 year ago.
CDIO has a better debt/assets ratio than last year.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CDIO has an Altman-Z score of 1.61. This is a bad value and indicates that CDIO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.61, CDIO is in the better half of the industry, outperforming 71.94% of the companies in the same industry.
CDIO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CDIO (0.03) is worse than 60.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.61
ROIC/WACCN/A
WACC10.05%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

CDIO has a Current Ratio of 13.92. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a better Current ratio (13.92) than 87.57% of its industry peers.
A Quick Ratio of 13.92 indicates that CDIO has no problem at all paying its short term obligations.
The Quick ratio of CDIO (13.92) is better than 87.57% of its industry peers.
Industry RankSector Rank
Current Ratio 13.92
Quick Ratio 13.92
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

4

3. Growth

3.1 Past

CDIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
CDIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 128.10%.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.26%
Revenue 1Y (TTM)128.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-5.84%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 2032.01% yearly.
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDIO. In the last year negative earnings were reported.
Also next year CDIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (5/9/2025, 8:00:02 PM)

After market: 0.185 0 (-0.05%)

0.1851

-0.03 (-12.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-14 2025-05-14
Inst Owners4.93%
Inst Owner Change0.03%
Ins Owners4.52%
Ins Owner Change0%
Market Cap9.65M
Analysts82.86
Price Target2.04 (1002.11%)
Short Float %3.83%
Short Ratio1.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.42%
Min EPS beat(2)41.18%
Max EPS beat(2)83.66%
EPS beat(4)3
Avg EPS beat(4)13.37%
Min EPS beat(4)-117.86%
Max EPS beat(4)83.66%
EPS beat(8)6
Avg EPS beat(8)16.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-87.12%
Min Revenue beat(2)-93.86%
Max Revenue beat(2)-80.39%
Revenue beat(4)0
Avg Revenue beat(4)-84.04%
Min Revenue beat(4)-93.86%
Max Revenue beat(4)-68.76%
Revenue beat(8)0
Avg Revenue beat(8)-90.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 276.59
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0
BVpS0.18
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.98%
ROE -87.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 146.24%
Cap/Sales 1158.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.92
Quick Ratio 13.92
Altman-Z 1.61
F-Score5
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)419.33%
Cap/Depr(5y)421.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.26%
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)128.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-5.84%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.97%
OCF growth 3YN/A
OCF growth 5YN/A